[{"address1": "2222 Ponce de Leon Boulevard", "address2": "Floor 3", "city": "Coral Gables", "state": "FL", "zip": "33134", "country": "United States", "phone": "786 629 1376", "website": "https://www.relmada.com", "industry": "Biotechnology", "sector": "Healthcare", "longBusinessSummary": "Relmada Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing various products for the treatment of central nervous system (CNS) diseases and other disorders. Its lead product candidate is Esmethadone (d-methadone, dextromethadone, and REL-1017), a new chemical entity and N-methyl-D-aspartate receptor antagonist that is in Phase 3 clinical trials for the adjunctive or monotherapy treatment of major depressive disorder in adults. The company was founded in 2004 and is headquartered in Coral Gables, Florida.", "fullTimeEmployees": 20, "companyOfficers": [{"maxAge": 1, "name": "Dr. Sergio  Traversa M.B.A., Pharm.D.", "age": 63, "title": "CEO & Director", "yearBorn": 1960, "fiscalYear": 2022, "totalPay": 719041, "exercisedValue": 0, "unexercisedValue": 34490}, {"maxAge": 1, "name": "Mr. Maged S. Shenouda M.B.A., R.Ph.", "age": 59, "title": "Chief Financial Officer", "yearBorn": 1964, "fiscalYear": 2022, "totalPay": 450353, "exercisedValue": 0, "unexercisedValue": 25070}, {"maxAge": 1, "name": "Mr. Charles S. Ence CPA, M.B.A.", "age": 58, "title": "Chief Accounting & Compliance Officer", "yearBorn": 1965, "fiscalYear": 2022, "totalPay": 568679, "exercisedValue": 0, "unexercisedValue": 2203}, {"maxAge": 1, "name": "Dr. Paolo  Manfredi M.D., Ph.D.", "age": 61, "title": "Chief Scientific Officer", "yearBorn": 1962, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Gina  DiGuglielmo", "title": "VP & Head of Clinical Operations", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Marco  Pappagallo M.D.", "age": 64, "title": "Chief Clinical Officer", "yearBorn": 1959, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. John  Hixon", "title": "Head of Commercial", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Andrew  Cutler", "title": "Senior Clinical Development Advisor", "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Richard M. Mangano", "age": 73, "title": "Consultant", "yearBorn": 1950, "fiscalYear": 2022, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 6, "boardRisk": 10, "compensationRisk": 9, "shareHolderRightsRisk": 4, "overallRisk": 9, "governanceEpochDate": 1711929600, "compensationAsOfEpochDate": 1672444800, "maxAge": 86400, "priceHint": 4, "previousClose": 4.66, "open": 4.61, "dayLow": 4.54, "dayHigh": 4.68, "regularMarketPreviousClose": 4.66, "regularMarketOpen": 4.61, "regularMarketDayLow": 4.54, "regularMarketDayHigh": 4.68, "beta": 0.191, "forwardPE": -1.9703391, "volume": 120017, "regularMarketVolume": 120017, "averageVolume": 217233, "averageVolume10days": 123440, "averageDailyVolume10Day": 123440, "bid": 4.62, "ask": 4.68, "bidSize": 400, "askSize": 300, "marketCap": 140310032, "fiftyTwoWeekLow": 2.36, "fiftyTwoWeekHigh": 7.223, "fiftyDayAverage": 5.3276, "twoHundredDayAverage": 3.61135, "currency": "USD", "enterpriseValue": 43986180, "floatShares": 25611863, "sharesOutstanding": 30174200, "sharesShort": 1694755, "sharesShortPriorMonth": 1754362, "sharesShortPreviousMonthDate": 1709164800, "dateShortInterest": 1711584000, "sharesPercentSharesOut": 0.056199998, "heldPercentInsiders": 0.082399994, "heldPercentInstitutions": 0.46277002, "shortRatio": 7.53, "shortPercentOfFloat": 0.0571, "bookValue": 2.836, "priceToBook": 1.6396333, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1703980800, "netIncomeToCommon": -98791744, "trailingEps": -3.28, "forwardEps": -2.36, "lastSplitFactor": "1:4", "lastSplitDate": 1569801600, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "RLMD", "underlyingSymbol": "RLMD", "shortName": "Relmada Therapeutics, Inc.", "longName": "Relmada Therapeutics, Inc.", "firstTradeDateEpochUtc": 1403271000, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "f101bc4b-2b97-3da3-a498-9e630b405138", "gmtOffSetMilliseconds": -14400000, "currentPrice": 4.65, "targetHighPrice": 25.0, "targetLowPrice": 3.0, "targetMeanPrice": 10.88, "targetMedianPrice": 7.75, "recommendationMean": 2.4, "recommendationKey": "buy", "numberOfAnalystOpinions": 4, "totalCash": 96323856, "totalCashPerShare": 3.192, "quickRatio": 7.899, "currentRatio": 7.996, "returnOnAssets": -0.51756, "returnOnEquity": -0.87505996, "freeCashflow": -17914348, "operatingCashflow": -51659208, "financialCurrency": "USD", "trailingPegRatio": null, "__fetch_time": "2024-04-13"}]